EORTC consensus recommendations on the optimal management of colorectal cancer liver metastases

Giacomo Bregni¹, Richard Adams², Reto Bale³, Maria A Bali⁴, Irene Bargellini⁵, Lennart Blomqvist⁶, Gina Brown⁷, Chiara Cremolini⁸, Pieter Demetter⁹, Timm Denecke¹⁰, Anthony Dohan¹¹, Cristina Dopazo¹², Elena Elez¹³, Serge Evrard¹⁴, Roger Feakins¹⁵, Matthias Guckenberger¹⁶, Marianne Gronlie Guren¹⁷, Maria Hawkins¹⁸, Anne Hoorens¹⁹, Emmanuel Huguet²⁰, Martijn Intven²¹, Thibaud Koessler²², Wolfgang G Kunz²³, Florian Lordick²⁴, Valerio Lucidi²⁵, Andreas H Mahnken²⁶, Hassan Malik²⁷, Philippe Martinive²⁸, Murielle Mauer²⁹, Alejandra Méndez Romero³⁰, Iris Nagtegaal³¹, Franco Orsi³², Wim Jg Oyen³³, Olivier Pellerin³⁴, Marco Rengo³⁵, Jens Ricke³⁶, Alexis Ricoeur³⁷, Angela Riddell³⁸, Maxime Ronot³⁹, Marta Scorsetti⁴⁰, Jenny Seligmann⁴¹, Christine Sempoux⁴², Kieran Sheahan⁴³, Stefan Stättner⁴⁴, Magali Svrcek⁴⁵, Julien Taieb⁴⁶, Nick West⁴⁷, Lucjan Wyrwicz⁴⁸, Christoph J Zech⁴⁹, Markus Moehler⁵⁰, Francesco Sclafani⁵¹

Affiliations

¹ Department of Gastrointestinal Oncology, Université libre de Bruxelles (ULB), Hôpital Universitaire de Bruxelles (HUB), Institut Jules Bordet, Brussels, Belgium.
² Velindre Cancer Centre, Cardiff University, Cardiff, UK.
³ Interventional Oncology, Stereotaxy and Robotics, Department of Radiology, Medical University Innsbruck, Innsbruck, Austria.
⁴ Department of Radiology, Université libre de Bruxelles (ULB), Hôpital Universitaire de Bruxelles (HUB), Institut Jules Bordet, Brussels, Belgium.
⁵ Candiolo Cancer Institute FPO-IRCCS, Department of Surgical Sciences, University of Turin, Italy.
⁶ Department of Nuclear Medicine/Hospital Physics, Karolinska University Hospital, Stockholm, Sweden.
⁷ Imperial College, London, UK.
⁸ Department of Translational Research and New Technologies in Medicine and Surgery, University of Pisa, Pisa, Italy.
⁹ Cerba Path, Division CMP, Brussels, Belgium; Laboratory for Experimental Gastroenterology, Université libre de Bruxelles (ULB), Brussels, Belgium.
¹⁰ Department of Diagnostic and Interventional Radiology, University of Leipzig Medical Center, University Cancer Center (UCCL), Leipzig, Germany.
¹¹ Department of Diagnostic and Interventional Radiology, Hôpital Cochin, AP-HP Centre, Université de Paris Cité, Paris, France.
¹² Department of HPB Surgery and Transplants, Vall d'Hebron Hospital Universitari, Vall d'Hebron Institut de Recerca (VHIR), Vall d'Hebron Barcelona Hospital Campus, Universitat Autónoma de Barcelona, Barcelona, Spain.
¹³ Vall d'Hebron Hospital Universitari, and Institute of Oncology (VHIO), Universitat Autònoma de Barcelona, Barcelona, Spain.
¹⁴ Institut Bergonié, University of Bordeaux, Bordeaux, France.
¹⁵ Royal Free London NHS Foundation Trust, London, UK.
¹⁶ University Hospital Zurich, University of Zurich, Zurich, Switzerland.
¹⁷ Department of Oncology, Oslo University Hospital, and Institute of Clinical Medicine, University of Oslo, Oslo, Norway.
¹⁸ University College London, Medical Physics and Biomedical Engineering, NIHR University College London Hospitals Biomedical Research Centre, London, UK.
¹⁹ Universitair Ziekenhuis Gent, Ghent, Belgium.
²⁰ Addenbrookes Hospital, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.
²¹ University Medical Center Utrecht, Utrecht, the Netherlands.
²² Geneva University Hospitals, Geneva, Switzerland.
²³ Department of Radiology, University Hospital, LMU Munich, Munich, Germany.
²⁴ Department of Oncology, Gastroenterology, Hepatology and Pulmonology, University of Leipzig Medical Center, University Cancer Center (UCCL), Leipzig, Germany.
²⁵ Department of Surgical Oncology, Université libre de Bruxelles (ULB), Hôpital Universitaire de Bruxelles (HUB), Hôpital Erasme, Brussels, Belgium.
²⁶ UKGM Marburg & Philipps-University of Marburg, Marburg, Germany.
²⁷ University Hospital Aintree, Liverpool, UK.
²⁸ Department of Radiation Oncology, Université libre de Bruxelles (ULB), Hôpital Universitaire de Bruxelles (HUB), Institut Jules Bordet, Brussels, Belgium.
²⁹ European Organisation for Research and Treatment of Cancer (EORTC), Brussels, Belgium.
³⁰ Department of Radiotherapy, Erasmus MC Cancer Institute, Erasmus University Medical Center, Rotterdam, the Netherlands.
³¹ Radboud University, Nijmegen, the Netherlands.
³² IRCCS Istituto Europeo di Oncologia, Milan, Italy.
³³ Humanitas University, Department of Biomedical Sciences, and IRCCS Humanitas Research Hospital, Department of Nuclear Medicine, Milan, Italy; Rijnstate, Department of Radiology and Nuclear Medicine, Arnhem, the Netherlands; Radboudumc, Department of Radiology and Nuclear Medicine, Nijmegen, the Netherlands.
³⁴ Department of Interventional Radiology, Georges Pompidou European Hospital SIRIC-CARPEM, Université Paris Cité, Paris, France.
³⁵ University of Rome Sapienza, Rome, Italy.
³⁶ University Hospital, LMU Munich, Munich, Germany.
³⁷ Radiology Division, Geneva University Hospitals, Geneva, Switzerland.
³⁸ The Royal Marsden NHS Foundation Trust, London, UK.
³⁹ Beaujon University Hospital, APHP Nord, Clichy, AND Université Paris Cité, Paris, France.
⁴⁰ Department of Radiotherapy and Radiosurgery, IRCCS Humanitas Research Hospital, and Department of Biomedical Sciences, Humanitas University, Milan, Italy.
⁴¹ Division of Oncology, Leeds Institute of Medical Research, University of Leeds, Leeds UK.
⁴² Institute of Pathology, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.
⁴³ Department of Pathology, St Vincent's University Hospital, and UCD School of Medicine, Dublin, Ireland.
⁴⁴ Salzkammergutklinikum, Vöcklabruck, Austria.
⁴⁵ Saint-Antoine Hospital, Sorbonne Université, Paris, France.
⁴⁶ Department of GI Oncology, Georges Pompidou European Hospital SIRIC-CARPEM, Université Paris Cité, Paris, France.
⁴⁷ Division of Pathology and Data Analytics, Leeds Institute of Medical Research, University of Leeds, Leeds UK.
⁴⁸ Maria Sklodowska Curie National Cancer Research Institute, Warsaw, Poland.
⁴⁹ Universitätsspital Basel, Universität Basel, Basel, Switzerland.
⁵⁰ Johannes Gutenberg University Clinic, Mainz, Germany.
⁵¹ Department of Gastrointestinal Oncology, Université libre de Bruxelles (ULB), Hôpital Universitaire de Bruxelles (HUB), Institut Jules Bordet, Brussels, Belgium. Electronic address: francesco.sclafani@hubruxelles.be.

PMID: 40179590
DOI: 10.1016/j.ctrv.2025.102926

Review

EORTC consensus recommendations on the optimal management of colorectal cancer liver metastases

Giacomo Bregni et al. Cancer Treat Rev. 2025 May.

. 2025 May:136:102926.

doi: 10.1016/j.ctrv.2025.102926. Epub 2025 Mar 27.

Authors

Affiliations

¹ Department of Gastrointestinal Oncology, Université libre de Bruxelles (ULB), Hôpital Universitaire de Bruxelles (HUB), Institut Jules Bordet, Brussels, Belgium.
² Velindre Cancer Centre, Cardiff University, Cardiff, UK.
³ Interventional Oncology, Stereotaxy and Robotics, Department of Radiology, Medical University Innsbruck, Innsbruck, Austria.
⁴ Department of Radiology, Université libre de Bruxelles (ULB), Hôpital Universitaire de Bruxelles (HUB), Institut Jules Bordet, Brussels, Belgium.
⁵ Candiolo Cancer Institute FPO-IRCCS, Department of Surgical Sciences, University of Turin, Italy.
⁶ Department of Nuclear Medicine/Hospital Physics, Karolinska University Hospital, Stockholm, Sweden.
⁷ Imperial College, London, UK.
⁸ Department of Translational Research and New Technologies in Medicine and Surgery, University of Pisa, Pisa, Italy.
⁹ Cerba Path, Division CMP, Brussels, Belgium; Laboratory for Experimental Gastroenterology, Université libre de Bruxelles (ULB), Brussels, Belgium.
¹⁰ Department of Diagnostic and Interventional Radiology, University of Leipzig Medical Center, University Cancer Center (UCCL), Leipzig, Germany.
¹¹ Department of Diagnostic and Interventional Radiology, Hôpital Cochin, AP-HP Centre, Université de Paris Cité, Paris, France.
¹² Department of HPB Surgery and Transplants, Vall d'Hebron Hospital Universitari, Vall d'Hebron Institut de Recerca (VHIR), Vall d'Hebron Barcelona Hospital Campus, Universitat Autónoma de Barcelona, Barcelona, Spain.
¹³ Vall d'Hebron Hospital Universitari, and Institute of Oncology (VHIO), Universitat Autònoma de Barcelona, Barcelona, Spain.
¹⁴ Institut Bergonié, University of Bordeaux, Bordeaux, France.
¹⁵ Royal Free London NHS Foundation Trust, London, UK.
¹⁶ University Hospital Zurich, University of Zurich, Zurich, Switzerland.
¹⁷ Department of Oncology, Oslo University Hospital, and Institute of Clinical Medicine, University of Oslo, Oslo, Norway.
¹⁸ University College London, Medical Physics and Biomedical Engineering, NIHR University College London Hospitals Biomedical Research Centre, London, UK.
¹⁹ Universitair Ziekenhuis Gent, Ghent, Belgium.
²⁰ Addenbrookes Hospital, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.
²¹ University Medical Center Utrecht, Utrecht, the Netherlands.
²² Geneva University Hospitals, Geneva, Switzerland.
²³ Department of Radiology, University Hospital, LMU Munich, Munich, Germany.
²⁴ Department of Oncology, Gastroenterology, Hepatology and Pulmonology, University of Leipzig Medical Center, University Cancer Center (UCCL), Leipzig, Germany.
²⁵ Department of Surgical Oncology, Université libre de Bruxelles (ULB), Hôpital Universitaire de Bruxelles (HUB), Hôpital Erasme, Brussels, Belgium.
²⁶ UKGM Marburg & Philipps-University of Marburg, Marburg, Germany.
²⁷ University Hospital Aintree, Liverpool, UK.
²⁸ Department of Radiation Oncology, Université libre de Bruxelles (ULB), Hôpital Universitaire de Bruxelles (HUB), Institut Jules Bordet, Brussels, Belgium.
²⁹ European Organisation for Research and Treatment of Cancer (EORTC), Brussels, Belgium.
³⁰ Department of Radiotherapy, Erasmus MC Cancer Institute, Erasmus University Medical Center, Rotterdam, the Netherlands.
³¹ Radboud University, Nijmegen, the Netherlands.
³² IRCCS Istituto Europeo di Oncologia, Milan, Italy.
³³ Humanitas University, Department of Biomedical Sciences, and IRCCS Humanitas Research Hospital, Department of Nuclear Medicine, Milan, Italy; Rijnstate, Department of Radiology and Nuclear Medicine, Arnhem, the Netherlands; Radboudumc, Department of Radiology and Nuclear Medicine, Nijmegen, the Netherlands.
³⁴ Department of Interventional Radiology, Georges Pompidou European Hospital SIRIC-CARPEM, Université Paris Cité, Paris, France.
³⁵ University of Rome Sapienza, Rome, Italy.
³⁶ University Hospital, LMU Munich, Munich, Germany.
³⁷ Radiology Division, Geneva University Hospitals, Geneva, Switzerland.
³⁸ The Royal Marsden NHS Foundation Trust, London, UK.
³⁹ Beaujon University Hospital, APHP Nord, Clichy, AND Université Paris Cité, Paris, France.
⁴⁰ Department of Radiotherapy and Radiosurgery, IRCCS Humanitas Research Hospital, and Department of Biomedical Sciences, Humanitas University, Milan, Italy.
⁴¹ Division of Oncology, Leeds Institute of Medical Research, University of Leeds, Leeds UK.
⁴² Institute of Pathology, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.
⁴³ Department of Pathology, St Vincent's University Hospital, and UCD School of Medicine, Dublin, Ireland.
⁴⁴ Salzkammergutklinikum, Vöcklabruck, Austria.
⁴⁵ Saint-Antoine Hospital, Sorbonne Université, Paris, France.
⁴⁶ Department of GI Oncology, Georges Pompidou European Hospital SIRIC-CARPEM, Université Paris Cité, Paris, France.
⁴⁷ Division of Pathology and Data Analytics, Leeds Institute of Medical Research, University of Leeds, Leeds UK.
⁴⁸ Maria Sklodowska Curie National Cancer Research Institute, Warsaw, Poland.
⁴⁹ Universitätsspital Basel, Universität Basel, Basel, Switzerland.
⁵⁰ Johannes Gutenberg University Clinic, Mainz, Germany.
⁵¹ Department of Gastrointestinal Oncology, Université libre de Bruxelles (ULB), Hôpital Universitaire de Bruxelles (HUB), Institut Jules Bordet, Brussels, Belgium. Electronic address: francesco.sclafani@hubruxelles.be.

PMID: 40179590
DOI: 10.1016/j.ctrv.2025.102926

Abstract

Patients with colorectal cancer liver metastases have long represented a unique and thoroughly investigated population. Nevertheless, the optimal management of these is still controversial with a number of open questions which are only partially addressed by available studies and existing guidelines. The European Organisation for Research and Treatment of Cancer (EORTC) Gastrointestinal Tract Cancer Group (GITCG) sought to fill this knowledge gap and promoted the development of a European consensus on this subject. By using the Delphi methodology and leveraging a multidisciplinary team of 43 international experts, including gastrointestinal oncologists, hepatobiliary surgeons, interventional radiologists, radiation oncologists, radiologists, nuclear medicine physicians and pathologists from 12 European countries, 34 practical recommendations and two consensus statements were proposed. These cover varying aspects of the optimal management of colorectal cancer liver metastases such as baseline imaging, selection criteria for liver-directed therapies, treatment strategies, assessment of treatment response, follow-up, care delivery, clinical research and future perspectives. This roadmap document is intended to complement national and international guidelines, and to provide practical guidance for clinicians and multidisciplinary teams, ultimately promoting practice standardisation, optimal management and better patient outcomes across Europe. Also, it provides a unique opportunity to highlight grey areas and unmet needs, and to give a strategic direction to future research in the field by identifying topics where there is no consensus among experts.

Keywords: Colorectal cancer; Delphi survey; EORTC; European consensus; Expert consensus; Liver metastases.

PubMed Disclaimer

Conflict of interest statement

Declaration of competing interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Reto Bale. Consulting fees from Interventional Systems. Stock or stock options from VSOPs Interventional Systems. Irene Bergellini. Consulting fees from Boston Scientific, Sirtex, Terumo Europe. Honoraria from Boston Scientific, Sirtex, Terumo Europe. Participation on a Data Safety Monitoring Board for AstraZeneca. Lennart Blomqvist. Royalty as Editor of Nordic Textbook of Radiology version 2. Co-founder and share holder of Collective Minds Radiology. Chiara Cremolini. Honoraria from Amgen, Merck, MSD, Pierre Fabre, Servier, Takeda. Payment for expert testimony for Bayer. Participation on a Data Safety Monitoring Board or Advisory Board for Lilly, Nordic Pharma, Roche, Rottapharm, Servier, Takeda. Timm Denecke: Honoraria from Bayer. Research grants from Bayer. Anthony Dohan. Honoraria from Terumo. Participation on a Data Safety Monitoring Board or Advisory Board for Terumo, Varian Medical. Elena Elez. Research grants from Abbvie Deutschland Gmbh & Co KG, Amgen Inc., Array Biopharma Inc, Astra Zeneca Pharmaceuticals LP, Bayer Pharma AG, BeiGene, Bioncotech, Therapeutics, S.L., Biontech Rna Pharmacuticals GMBH, Biontech Small Molecules GMBH, Boehringer Ingelheim, Boehringer Ingelheim de España S.A., Bristol-Myers Squibb International Corporation, Celgene International SARL, Daiichi Sankyo, Inc, Debiopharm International SA, Genentech Inc, Gercor, HalioDX SAS, Hoffmann-La Roche Ltd, Hutchinson Medipharma Limited, Hutchison MediPharma, International, Iovance Biotherapeutics, Inc., Janssen Research & Development, Janssen-Cilag SA, MedImmune, Menarini, Menarini Ricerche SPA, Merck Health KGAA, Merck, Sharp & Dohme de España S.A., Merus NV, Mirati, Nouscom SRL., Novartis Farmacéutica SA, Pfizer, PharmaMar SA, Pledpharma AB, Redx Pharma PLC, Sanofi Aventis Recherche & Développement, Scandion Oncology, Seattle Genetics Inc., Servier, Sotio A.S., Taiho Pharma USA Inc, Wntresearch AB. Consulting fees from Agenus, Amgen, Bayer, BMS, Boehringer Ingelheim, Cure Teq AG, GlaxoSmithKline, Hoffman La – Roche, Janssen, Lilly, Medscape, Merck Serono, MSD, Novartis, Organon, Pfizer, Pierre Fabre, Repare Therapeutics Inc., RIN Institute Inc., Sanofi, Seagen International, GmbH, Servier, Takeda. Honoraria from Agenus, Amgen, Bayer, BMS, Boehringer Ingelheim, Cure Teq AG, GlaxoSmithKline, Hoffman La – Roche, Janssen, Lilly, Medscape, Merck Serono, MSD, Novartis, Organon, Pfizer, Pierre Fabre, Repare Therapeutics Inc., RIN Institute Inc., Sanofi, Seagen International, GmbH, Servier, Takeda. Travel grants from Agenus, Amgen, Bayer, BMS, Boehringer Ingelheim, Cure Teq AG, GlaxoSmithKline, Hoffman La – Roche, Janssen, Lilly, Medscape, Merck Serono, MSD, Novartis, Organon, Pfizer, Pierre Fabre, Repare Therapeutics Inc., RIN Institute Inc., Sanofi, Seagen International, GmbH, Servier, Takeda. Participation on a Data Safety Monitoring Board or Advisory Board for Agenus, Amgen, Bayer, BMS, Boehringer Ingelheim, Cure Teq AG, GlaxoSmithKline, Hoffman La – Roche, Janssen, Lilly, Medscape, Merck Serono, MSD, Novartis, Organon, Pfizer, Pierre Fabre, Repare Therapeutics Inc., RIN Institute Inc., Sanofi, Seagen International, GmbH, Servier, Takeda. Leadership roles for the European Society of Medical Oncology (ESMO), the American Society of Clinical Oncology (ASCO), and the Sociedad Española de Oncología Médica (SEOM). Roger Feakins. Consulting fees from Abbvie, DeciBio, Alimentiv plc. Honoraria from Janssen. Leadership roles for the European Society of Pathology (ESP), and the British Society of Gastroenterology (BSG). Matthias Guckenberger. Research grants from Varian/Siemens Healthineers, ViewRay. Consulting fees for Astra Zeneca. Leadership role for the European Society for Radiotherapy and Oncology (ESTRO). Marianne G Guren. Research grants from the Norwegian Cancer Society, Health Region South-Est. Participation on a Data Safety Monitoring Board or Advisory Board for academic trials. Leadership role for the Norwegian Colorectal Cancer Group. Institutional payment for participation in pharma-sponsored clinical trials. Thibaud Koessler. Consulting fees from AstraZeneca, Bayer, BMS, Boehringer Ingelheim, GSK, Lilly, Merck, MSD, Novartis, Pierre-Fabre, Roche, Takeda, Vifor. Honoraria from AstraZeneca, Bayer, BMS, Boehringer Ingelheim, GSK, Lilly, Merck, MSD, Novartis, Pierre-Fabre, Roche, Takeda, Vifor. Payment for expert testimony from Astra Zeneca. Travel grants from Lilly, Ipsen, Sanofi, Pierre-Fabre, AstraZeneca, Daiichi Sankyo. Participation on a Data Safety Monitoring Board or Advisory Board for Boehringer Ingelheim. Wolfgang G Kunz. Honoraria from BMS, Boehringer Ingelheim, mintMedical, Need Inc. Martijn Intven. Honoraria from Elekta. Leadership roles for the Dutch Society of Radiotherapy and Oncology. Florian Lordick. Research grants from Astra Zeneca, BMS, Gilead. Consulting fees from Amgen, Astellas, Bayer, Beigene, Biontech, BMS, Eli Lilly, MSD, PAGE, Roche, Servier. Honoraria from Astellas, Astra Zeneca, BMS, Daiichi Sankyo, Eli Lilly, Medscape, MedUpdate, Merck, MSD, Roche, Servier, StreamedUp!. Travel grants from Daiichi Sankyo. Participation on a Data Safety Monitoring Board or Advisory Board for Biontech. Leadership roles for the European Society of Medical Oncology (ESMO), the International Gastric Cancer Association (IGCA), and the International Cancer Foundation. Wim JG Oyen. Honoraria from Novartis. Participation on a Data Safety Monitoring Board or Advisory Board for Bayer. Franco Orsi. Honoraria from Medtronic. Alexis Ricoeur: Honoraria from Astra Zeneca. Travel grants from Abbott, Boston Scientific, Terumo. Maxime Ronot. Honoraria from Angiodynamics, AstraZeneca, General Electrics, Guerbet, Servier, Sirtex, Terumo. Jenny Seligmann. Research grants from Amgen, GSK, Merck Serono. Consulting fees for Astra Zeneca, BMS, Merck Serono, Sanofi, Servier, Takeda. Honoraria from GSK, Elevation Oncology, GI Connect, Merck Serono, Servier, Takeda. Travel grants from Takeda. Participation on a Data Safety Monitoring Board or Advisory Board for GSK. Stefan Stättner. Honoraria from Astra Zeneca, BMS, Incyte, Mölnlycke, Roche, Takeda. Advisory board for Astra Zeneca. Educational grants from ITM Pharma. Julien Taieb. Consulting fees from Amgen, Astelllas, Astra Zeneca, BMS, Boehringer, Merck KGaA, MSD, Novartis, ONO pharmaceuticals, Pierre Fabre, Roche Genentech, Sanofi, Servier and Takeda. Honoraria from Amgen, Astelllas, Astra Zeneca, BMS, Boehringer, Merck KGaA, MSD, Novartis, ONO pharmaceuticals, Pierre Fabre, Roche Genentech, Sanofi, Servier and Takeda. Nick West: Research grants from Yorkshire Cancer Research, Cancer Research UK, National Institute for Health and Care Research, Pierre Fabre, GSK. Consulting fees from Amgen, Astellas, BMS, GSK, Pfizer. Markus Moehler. Research grants from Amgen, Astra Zeneca, Leap Therapeutics, Merck Serono, MSD, Taiho Pharmaceutical. Honoraria from Amgen, Astellas Pharma, Astra Zeneca/MedImmune, Bayer Schering Pharma, BMS, Daiichi Sankyo Europe GmbH, Idience, Merck Serono, MSD Oncology, Pierre Fabre, Roche/Genentech, Sanofi, Servier, Transcenta, Triptych Health Partners. Travel grants from Amgen, Astra-Zeneca, BeiGene, BMS, Daiichi Sankyo Europe GmbH, Takeda. Participation on a Data Safety Monitoring Board or Advisory Board for Amgen, Astra Zeneca, Bayer, BeiGene, BMS, Daiichi Sankyo Europe GmbH, Lilly, Merck Serono, MSD, Nordic Group, Servier, Taiho Pharmaceutical, Takeda. Leadership roles for the European Organisation for Research and Treatment of Cancer (EORTC), Arbeitsgemeinschaft Internistische Onkologie (AIO), and Johannes Gutenberg Universität (JGU) Mainz. Francesco Sclafani. Honoraria from Amgen, Merck, Servier. Participation on a Data Safety Monitoring Board or Advisory Board for AMAL Therapeutics, Bayer, BMS, Dragonfly Therapeutics, GSK, Nordic Pharma, Roche. Research grants from Amgen, Association Jules Bordet, Astellas, Astra Zeneca, Bayer, Belgian Health Care Knowledge Centre (KCE), BMS, Fondation Contre le Cancer, Horizon Europe, Merck, MSD, Pierre Fabre, Roche, Sanofi, Televie/FNRS. Travel grants from Amgen, Bayer, Lilly, Merck, Roche, Servier. Leadership roles for the European Organisation for Research and Treatment of Cancer (EORTC), All the other authors do not have any conflict of interest.

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- ClinicalKey
- Elsevier Science
Medical
- MedlinePlus Health Information
Miscellaneous
- NCI CPTAC Assay Portal

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

EORTC consensus recommendations on the optimal management of colorectal cancer liver metastases

Affiliations

EORTC consensus recommendations on the optimal management of colorectal cancer liver metastases

Authors

Affiliations

Abstract

Conflict of interest statement

Publication types

MeSH terms

LinkOut - more resources

Full Text Sources

Medical

Miscellaneous